Search Results

Art collage, hands and scales of justice. The concept of the law of the judge.

Legal

Former CytoDyn Official Found Guilty of Securities Fraud

Former president and CEO of CytoDyn Nader Pourhassan along with Kazem Kazempour, former CEO of the CRO running CytoDyn’s trials, are awaiting sentencing but could face up to 20 years in prison for each count of securities and wire fraud and insider trading.

December 12, 2024

·

2 min read

·

Tristan Manalac

Press Releases

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

February 24, 2025

·

3 min read

Press Releases

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

February 6, 2025

·

4 min read

BioForest

CytoDyn to Host Webcast to Provide Company Update

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024.

May 28, 2024

·

4 min read

Drug Development

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

CytoDyn Inc. announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024.

June 27, 2024

·

4 min read

Press Releases

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

November 25, 2024

·

4 min read

Press Releases

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

November 4, 2024

·

3 min read

Policy

CytoDyn Announces FDA Has Lifted Clinical Hold

CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the FDA has lifted the clinical hold on leronlimab.

February 29, 2024

·

4 min read

Press Releases

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

September 24, 2024

·

2 min read

Drug Development

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA.

February 1, 2024

·

5 min read